<DOC>
	<DOCNO>NCT00064246</DOCNO>
	<brief_summary>Phase I/II trial study effectiveness combine yttrium Y 90 ibritumomab tiuxetan rituximab treat patient localized recurrent lymphoproliferative disorder organ transplant . Monoclonal antibody yttrium Y 90 ibritumomab tiuxetan rituximab locate cancer cell either kill deliver radioactive cancer-killing substance without harm normal cell</brief_summary>
	<brief_title>Yttrium Y 90 Ibritumomab Tiuxetan Rituximab Treating Patients With Post-Transplant Lymphoproliferative Disorder</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ) patient post-transplant lymphoproliferative disorder . II . Determine safety toxicity profile IDEC-Y2B8 rituximab patient . III . Correlate Epstein-Barr virus viral load response relapse patient treat regimen . OUTLINE : This multicenter , dose-escalation study yttrium Y 90 ibritumomab tiuxetan ( IDEC-Y2B8 ) . Phase I : Patients receive rituximab IV indium In 111 ibritumomab tiuxetan IV 10 minute day 1 . Patients undergo 2 ( 3 need ) image scans day 1-6 . In absence alter biodistribution , patient receive rituximab IV follow within 4 hour IDEC-Y2B8 IV 10 minute day 8.Cohorts 6 patient receive escalate dos IDEC-Y2B8 maximum tolerate dose ( MTD ) determine . The MTD define dose 1 6 patient experience dose-limiting toxicity . Phase II : Patients receive treatment phase I MTD IDEC-Y2B8 . Patients follow monthly 3 month , every 3 month 2 year , every 6 month 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm posttransplant lymphoproliferative disorder ( PTLD ) 1 follow stage : Stage III IV Localized ( amenable localize radiotherapy excision ) Recurrent The following histologies* eligible : Polyclonal PTLD Monoclonal PTLD Diffuse large Bcell nonHodgkin 's lymphoma ( NHL ) Lymphoplasmacytic NHL Burkitt/Burkittlike NHL Must completely respond OR progress prior rituximab without chemotherapy No history rapid disease progression receive prior chemotherapy Measurable disease Must le 25 % bone marrow involvement lymphoma Prior solid organ transplantation require Evaluation malignant cell EpsteinBarr virus ( EBV ) require EBV positive negative allow No pleural effusion No CNS lymphoma , include leptomeningeal disease No pulmonary involvement NHL patient prior lung transplantation No HIV AIDSrelated lymphoma No hypocellular bone marrow ( i.e. , less 15 % cellularity ) No marked reduction bone marrow precursor one cell line ( i.e. , granulocytic , megakaryocytic , erythroid ) Performance status Karnofsky 50100 % At least 3 month Absolute neutrophil count least 1,500/mm^3 Platelet count least 150,000/mm^3 Bilirubin great 2.5 mg/dL Creatinine great 2.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation HIV negative No serious nonmalignant disease infection would compromise study objectives No presence antimurine antibody reactivity No concurrent active malignancy require therapy More 2 week since prior filgrastim ( GCSF ) sargramostim ( GMCSF ) More 6 week since prior rituximab No prior allogeneic bone marrow hematopoietic stem cell transplantation No prior radioimmunotherapy NHL More 4 week since prior chemotherapy See Biologic therapy No prior radiotherapy 25 % active bone marrow ( involved field regional ) More 4 week since prior major surgery except diagnostic surgery No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>